Literature DB >> 27858716

Skin Autofluorescence Examination as a Diagnostic Tool for Mild Cognitive Impairment in Healthy People.

Michiya Igase1, Maya Ohara1, Keiji Igase2, Takeaki Kato1, Yoko Okada1, Masayuki Ochi1, Yasuharu Tabara3, Katsuhiko Kohara4, Yasumasa Ohyagi1.   

Abstract

BACKGROUND: Accumulation of advanced glycation endproducts (AGEs) is thought to be involved in the pathogenesis of dementia, especially Alzheimer's disease. Tissue AGE accumulation can be estimated using the relative simple noninvasive measurement of skin autofluorescence (SAF), a method based on the fluorescent properties of some AGEs. However, possible involvement of tissue AGE accumulation in mild cognitive impairment (MCI) has not been fully investigated.
OBJECTIVE: We investigated whether tissue AGE accumulation estimated by SAF is associated with mild cognitive impairment.
METHODS: We analyzed 226 community-dwelling subjects. In addition to several atherosclerosis-related clinical parameters, MCI screening test, assessment of brain atrophy, and SAF were performed on people aged > 40 years. MCI was assessed using the Japanese version of the MCI screening method. Atrophy of the brain was assessed by examining the temporal horn area (THA) by brain MRI.
RESULTS: SAF was significantly higher in participants with MCI than in those with normal cognitive function (2.56±0.55 versus 2.10±0.41; p < 0.001). Logistic regression analyses with adjustment for confounding factors including age and THA showed that high SAF > 2.27 was significantly related to the presence of MCI (odds, 6.402; 95% CI, 1.590-25.773, p = 0.009).
CONCLUSION: We found an association between SAF and MCI, which was independent of brain atrophy, in healthy subjects.

Entities:  

Keywords:  Advanced glycation endproducts; brachial ankle pulse wave velocity; brain natriuretic peptide; estimated glomerular filtration rate; mild cognitive impairment; skin auto fluorescence; temporal horn area

Mesh:

Substances:

Year:  2017        PMID: 27858716     DOI: 10.3233/JAD-160917

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  2 in total

1.  Use of skin advanced glycation end product levels measured using a simple noninvasive method as a biological marker for the diagnosis of neuropsychiatric diseases.

Authors:  Hiroki Yamashita; Eriko Fukushima; Kaori Shimomura; Hitoki Hirose; Ken Nakayama; Narihiro Orimo; Wanyi Mao; Narimasa Katsuta; Shohei Nishimon; Tohru Ohnuma
Journal:  Int J Methods Psychiatr Res       Date:  2020-04-23       Impact factor: 4.035

2.  Are Advanced Glycation End Products in Skin Associated with Vascular Dysfunction Markers? A Meta-Analysis.

Authors:  Alicia Saz-Lara; Celia Álvarez-Bueno; Vicente Martínez-Vizcaíno; Blanca Notario-Pacheco; Irene Sequí-Dominguez; Iván Cavero-Redondo
Journal:  Int J Environ Res Public Health       Date:  2020-09-22       Impact factor: 3.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.